U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07450313) titled 'The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT' on Feb. 09.
Brief Summary: This study aims to evaluate whether luspatercept can improve the efficacy and safety of anemia treatment in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation.
Study Start Date: March 14
Study Type: INTERVENTIONAL
Condition:
HSCT
Intervention:
DRUG: Luspatercept
Subjects will be screened according to the inclusion and exclusion criteria. Eligible patients enrolled will receive treatment with Luspatercept at a dose of 1.0 mg/kg, administered subcutaneously as a single dose on day...